STAT+: Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research pipeline, CEO Reshma Kewalramani said Monday at the virtual J.P. Morgan Healthcare Conference.
The company also sees more growth for its cystic fibrosis drug business. There are approximately 83,000 cystic fibrosis patients amenable to treatment with Vertex medicines in the U.S., Europe, Australia, and Canada, based on Vertex’s latest forecasts, an increase of 8,000 patients from its previous estimate.
